Clinical Trials Logo

Anorexia clinical trials

View clinical trials related to Anorexia.

Filter by:

NCT ID: NCT00584688 Terminated - Anorexia Nervosa Clinical Trials

A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study

Start date: February 2007
Phase: Phase 2
Study type: Interventional

Research studies raise the possibility that medications such as quetiapine may improve mood or reduce obsessions in people with anorexia nervosa and may even help to normalize appetite. The medication quetiapine also known as seroquel works by activating certain systems in the brain, such as ones known as dopamine and serotonin chemical systems in the brain.

NCT ID: NCT00558558 Terminated - Weight Loss Clinical Trials

Haelan and Nutrition in Cancer Patients

Start date: October 2007
Phase: Phase 2
Study type: Interventional

Primary: - To determine if treatment with Haelan (fermented soy product) can decrease the severity of poor appetite measured using a visual analog scale (VAS) of 0 to 100 mm (0 mm = best, 100 mm = worst) at week 4 +/- 5 days. - To determine if treatment with Haelan can decrease the severity of nausea, fatigue, and improve patients' overall sense of well being measured using a VAS of 0 to 100 mm (0 mm = best, 100 mm = worst) at week 4 +/- 5 days. - To determine if treatment with Haelan can increase patient's calorie intake, albumin, pre-albumin, anthropometric measure, lean body mass (measured by bio-impedence analysis), and weight at week 4+/- 5 days. - To determine if treatment with Haelan can decrease patient's Functional assessment of anorexia/cachexia therapy subscales or (FAACT) and the Functional Assessment of Chronic Illness Therapy with fatigue subscales (FACIT-F) at week 4+/- 5 days. - To assess the feasibility of accrual, and adherence to the Haelan consumption. Secondary: - Determine the plasma isoflavone activity, 12-MTA and 13-MTA of these patients. - Correlate the biologic modulation of peripheral blood lymphocyte NF-kB by Haelan with primary outcome in these patients. - To determine if treatment with Haelan can increase patient's functional status at week 4+/- 5 days.

NCT ID: NCT00535015 Terminated - Clinical trials for Carcinoma, Non-Small-Cell Lung

Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer

Start date: October 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether Betamarc is effective in improving the appetite and reversing weight loss in patients with advanced Non-Small Cell Lung Cancer.